Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors’ reply

Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors' reply.

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab

Crohn's disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate re...

Vedolizumab for the treatment of inflammatory bowel disease.

The causes of inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn's disease (CD), remain to be elucidated. However, characteristic inflammation of the gastrointestinal mucosa is caused by infiltration of T lymphocytes into the submucosal layer. Inhibiting this immune response is a promising therapeutic target. Integrins expressed on the cell surface mediate gut homing of T ly...

Neonatal Presentation of Unremitting Inflammatory Bowel Disease

Very-early-onset inflammatory bowel disease (VEO-IBD) has a distinct phenotype and should be considered a specific entity. VEO-IBD presents with very severe clinical pictures and is frequently known by an indeterminate colitis whose clinical remission is unmanageable. This study examines the case of a neonate with VEO-IBD, not responding to medical and surgical treatment. A 7-day-old Iranian fe...

Inflammatory bowel disease in liver transplanted patients

Most common hepatobiliary manifestation of inflammatory bowel disease (IBD) are primary sclerosing cholangitis (PSC) and autoimmune hepatitis, ranking them as the main cause of liver transplantation (LT) in IBD setting. Course of pre-existing IBD after LT differs depending on many transplant related factors. Potential risk factors related to IBD deterioration after LT are tacrolimus-based immun...